Meeting
2022 ASCO Annual Meeting
Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
Authors
Jacob Stephen Thomas
Division of Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA
Jacob Stephen Thomas , Anthony B. El-Khoueiry , Anthony J. Olszanski , Nilofer Saba Azad , Giles Francis Whalen , Diana L. Hanna , Matthew Ingham , Luis H. Camacho , Syed Mahmood , Lewis H. Bender , Ian B. Walters , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT03058289
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2520)
DOI
10.1200/JCO.2022.40.16_suppl.2520
Abstract #
2520
Poster Bd #
176
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
![A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.](https://d201v5jt9ylckg.cloudfront.net/273/13618/196128/196128_A711_poster_pv.jpg)
A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.
First Author: Anthony B. El-Khoueiry
Poster
2020 ASCO Virtual Scientific Program
Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
First Author: Jacob Stephen Thomas
Poster
2023 ASCO Annual Meeting
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
First Author: Christian Frederick Meyer
Poster
2023 ASCO Annual Meeting
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
First Author: Jiaxin Niu